Thoracic Surgery

In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return. The study is going to test whether or not the number of circulating cancer cells detected in the blood can be reduced by administration durvalumab after the standard treatment if you are tested positive for the residual cancer.

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Eligibility:
Inclusion Criteria: - Patients undergoing esophagectomy
Exclusion Criteria:
- Patients with more than mild pulmonary dysfunction
- Patients with any neuromuscular disease that might compromise diaphragm function
- Patients with abnormal liver or kidney function
- Patients taking any immunosuppressant medication (including prednisone) or antifungal medications
- History of tuberculosis
- Weight loss of >5% of body weight over previous 6 months
- Pregnancy

The purpose of this study is to prevent unnecessary overtreatment of GGOs in humans and determine the efficacy of active surveillance as a management technique. This is a registry trial for the active surveillance of patients with multiple ground glass opacities (GGOs) in the lung identified on imaging. The presence of these lesions often prompts biopsy or resection to exclude the possibility of malignancy. However, as these GGOs tend to be low-risk, indolent lesions, we hypothesize that a more conservative approach of active surveillance may be reasonable and safe for managing these patients. By employing a strategy of close observation and a registry format, we can assess the efficacy of this approach and obtain important prospective data about the natural history of these lesions. This study hypothesizes that a strategy of active surveillance for GGOs will be feasible and safe which could potentially spare patients from overtreatment and unnecessary surgeries.

Eligibility: Patients presenting with two or more GGOs on computed tomography (CT) imaging will be enrolled in the active surveillance registry

The purpose of this study is to determine the best dose and timing of infusion for investigational imaging dye, Panitumumab-IRDye800, in patients undergoing surgery for suspected lung cancer. Investigators believe Panitumumab-IRDye800 will bind to cancer lesions make it easier to separate cancer tissue from normal tissue when looking under near-infrared (NIR) light. Being able to better visualize cancer cells during surgery could help surgeons remove sub-clinical (too small to see) and metastatic (separate from main tumor) cancer cells; leading to better treatment rates. In this study, participants will undergo standard of care minimally-invasive surgical resection of a lung nodule or mass. The study will test 3 different doses of Panitumumab-IRDye800 and two infusion windows (1-2 days prior to surgery or 3-5 days prior to surgery) to determine the best imaging conditions.

Eligibility: Patients with lung nodule or mass concerning for malignancy, either primary lung cancer or lung metastases, whether or not it is biopsy-proven. Patients scheduled to undergo planned standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent for lung cancer. Age ≥ 19 years

We hope to learn whether a personalized telephone-based exercise program will help you recover from lung surgery. If you agree to participate in this study, you will be asked to identify a family caregiver to participate along with you, but you are not required to have a family caregiver participate with you.

This study aims to compare the impact of telephone-based physical activity coaching vs. physical activity self-monitoring only on patient physical function. Furthermore, we aim to compare the impact of telephone-based physical activity coaching vs. physical activity self-monitoring only on patient-centered outcomes, including patient functional capacity, patient and FCG self-efficacy, patient and family caregiver quality of life, and on patient surgical/clinical outcomes and healthcare resource use.

Upon consent, participants will partake in questionnaires, in-person assessments, and participate in a self-monitoring or telephone-coaching exercise group.

The telephone-coaching group will receive the telephone-based physical activity coaching sessions which are delivered by a rehabilitation therapist and a research nurse. The telephone coaching will be given in 5 sessions, and each session will last between 20 to 50 minutes. The telephone sessions will be scheduled by research staff.

The self-monitoring group will receive print materials on physical activity developed by the American Society of Clinical Oncology either in person or by mail. Research staff will be available to answer any questions you have about the information provided. You will not receive any telephone coaching calls.

Research staff will be assessing your exercise tolerance through several physical assessments. These assessments will occur at the beginning of the study, and again at 4 additional time points (at hospital discharge, 30, 60, and 180 days after discharge). The assessments include a 6-minute walk test, where research staff will determine the distance that you can walk, at your own pace, for 6 minutes. There is also a brief assessment of your lower extremity strength that includes measuring how quickly you can stand from sitting in a chair and how well you can balance on your legs. The assessments will take about 15 minutes to complete.

Eligibility: This study will be available to patients who are 65 years old or older and are undergoing surgery for lung cancer or for suspected lung cancer.